Zika Vaccine Partnership Announced
England-based Enesi Pharma announced on September 3, 2020, its partnership with the University of Adelaide to develop a new thermostable, solid dose DNA vaccine for the Zika virus to prevent infection of pregnant women and the resultant congenital effects in unborn children. No date for launching a phase 1 study was announced.
DNA and RNA vaccines present important thermostability challenges and require an uninterrupted end-to-end cold chain throughout to maintain potency up to the point of administration. Enesi’s ImplaVax® technology aims to address these challenges by creating needle-free, solid dose vaccines, that are thermally stable at temperatures up to 40oC and eliminate the need for cold-chain storage and distribution.